Physician profile
Daniel R Conlin
NPI 1952439713
$6,936.50
in general payments reported to CMS, 2019-2025
32 companies · $981 in 2025
The $981 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,002 · 2021: $616 · 2022: $649 · 2023: $913 · 2024: $928 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,541.61 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Gilead Sciences, INC. | $956.05 | 2019-2025 | |
| Braintree Laboratories, INC. | $833.06 | 2019-2023 | Suflave |
| Janssen Biotech, INC. | $649.31 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $599.60 | 2019-2025 | Entyvio |
| Pfizer INC. | $441.94 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.47 | 2019-2024 | Xifaxan |
| Celltrion USA INC. | $239.85 | 2024-2025 | Vegzelma |
| Qol Medical, LLC | $225.40 | 2020-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $166.90 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $112.12 | 2019-2024 | |
| Celgene Corporation | $78.60 | 2021-2024 | Zeposia |
| Romark Laboratories, Lc | $74.12 | 2019-2020 | |
| Lilly USA, LLC | $67.73 | 2024-2025 | Omvoh |
| Shire North American Group INC | $49.79 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46.96 | 2023 | |
| Medtronic, INC. | $46.37 | 2024 | Gi Genius |
| Napo Pharmaceuticals INC | $40.64 | 2019 | |
| Concordia Pharmaceuticals INC. | $40.64 | 2019 | |
| Sandoz INC. | $39.65 | 2023 | Hyrimoz |
| Aimmune Therapeutics, INC. | $39.28 | 2025 | Zenpep |
| Amgen INC. | $28.23 | 2022 | |
| Alfasigma USA, INC. | $25.17 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $24.65 | 2024 | Iqirvo |
| Novo Nordisk INC | $24.28 | 2025 | Wegovy |
| Ardelyx, INC. | $21.64 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $20.83 | 2024 | Voquezna |
| Fresenius Kabi USA, LLC | $18.70 | 2023 | Idacio |
| Nestle Healthcare Nutrition INC. | $18.53 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $16.81 | 2025 | Dupixent |
| Redhill Biopharma INC. | $15.63 | 2020 | |
| Merck Sharp & Dohme LLC | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Conlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.